Recombinant human deoxyribonuclease I

Thins and loosens mucus in the airways

Phase of research

FDA-/EMA-approved for Cystic Fibrosis

How it helps

Mucociliary Clearance

General information

N/A

Synonyms

rhDNase, Dornase Alfa

Marketed as

Dietary sources

N/A

Structure image not available

N/A

Drug-Mutation Relation

Treats

Mutation Number of sources Average impact factor
General effect
9 5.53
Link Tested on Impact factor Notes
The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis. humans 5.90
Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis humans N/A As effective as Hypertonic Saline.
Effect of Aerosolized Recombinant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients with Cystic Fibrosis humans N/A
Effects of 12-Week Administration of Dornase Alfa in Patients with Advanced Cystic Fibrosis Lung Disease humans 2.34
Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial. humans 6.53 As effective as mannitol.
DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha. humans 1.59
A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. humans 3.54
Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. humans 13.25 More effective than hypertonic saline.
Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis. humans N/A

Does not treat

Mutation Number of sources Average impact factor